Nitro-imidazole antimycobacterial agent

This page covers all Nitro-imidazole antimycobacterial agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Mycolic acid biosynthesis pathway (mycobacterial cell wall).

Targets

Mycolic acid biosynthesis pathway (mycobacterial cell wall)

Phase 3 pipeline (1)

• Delamanid + OBR · Otsuka Pharmaceutical Development & Commercialization, Inc. · Infectious Disease
  Delamanid inhibits mycobacterial cell wall synthesis by targeting mycolic acid production, while OBR (optimized background regimen) provides synergistic anti-tuberculous activity through multiple complementary mechanisms.

Patent intelligence

• nitro imidazole antimycobacterial agent patent landscape — aggregated cliff calendar, attackable patents, originator estates